高级检索
袁叶敏, 李士雪, 周成超. 结核分枝杆菌潜伏感染治疗接受性及影响因素[J]. 中国公共卫生, 2023, 39(7): 942-947. DOI: 10.11847/zgggws1140222
引用本文: 袁叶敏, 李士雪, 周成超. 结核分枝杆菌潜伏感染治疗接受性及影响因素[J]. 中国公共卫生, 2023, 39(7): 942-947. DOI: 10.11847/zgggws1140222
YUAN Yemin, LI Shixue, ZHOU Chengchao. Acceptance and influencing factors of preventive treatment for latent tuberculosis infection: a review[J]. Chinese Journal of Public Health, 2023, 39(7): 942-947. DOI: 10.11847/zgggws1140222
Citation: YUAN Yemin, LI Shixue, ZHOU Chengchao. Acceptance and influencing factors of preventive treatment for latent tuberculosis infection: a review[J]. Chinese Journal of Public Health, 2023, 39(7): 942-947. DOI: 10.11847/zgggws1140222

结核分枝杆菌潜伏感染治疗接受性及影响因素

Acceptance and influencing factors of preventive treatment for latent tuberculosis infection: a review

  • 摘要: 对结核分枝杆菌潜伏感染者进行预防性治疗是实现终止结核病目标关键措施之一。目前,关于不同人群预防性治疗的接受性尚不清楚。本文综述了国内外结核分枝杆菌潜伏感染预防性治疗接受性研究现状及其影响因素,以期为相关部门开展结核分枝杆菌潜伏感染预防性治疗,制定相关政策提供理论依据和参考。

     

    Abstract: Preventive treatment for latent tuberculosis infection is one of the key measures to achieve the goal of ending tuberculosis. Currently, the acceptance of preventive treatment among different populations is unclear. In this review, we summarized the status quo and influencing factors of acceptance for preventive treatment of latent tuberculosis infection at home and abroad for providing a reference to the conduction of preventive treatment of latent tuberculosis infection and policy formulation by relevant departments.

     

/

返回文章
返回